— Published date: 6/2/2026
Value proposition: CAR-engineered cDC1 cells (syngeneic or allogeneic) that stably express a proprietary, modular chimeric antigen receptor and demonstrate strong in vivo efficacy against solid tumors, including immunologically ‘cold’ tumors.
Technology Desc…
— Published date: 5/30/2026
Value Proposition: CAR-engineered cDC1 cells (syngeneic or allogeneic) that stably express a proprietary, modular chimeric antigen receptor and demonstrate strong in vivo efficacy against solid tumors, including immunologically ‘cold’ tumors.
Technology Descr…
— Published Date: 5/14/2025
Value proposition: Self-sustaining chimeric macrophages as a novel approach to target amyloid plaques resulting in improved efficacy and survival in patients.
Technology Description
Researchers from Washington University in St. Louis have engineered macrophages to expre…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
